GastroCE
  1. Home
  2. Ulcerative Colitis
  3. Optimal Use of Biologics and Biosimilars in IBD: What, When, and in Whom?

This activity is expired and is no longer available for CME credit.

CME Information

LECTURECME

Optimal Use of Biologics and Biosimilars in IBD: What, When, and in Whom?

Author(s)/Faculty: David T. Rubin, MD, FACG, AGAF, FACP, FASGE; Iris Dotan, MD; Bruce E. Sands, MD, MS
Release Date: 7/20/2018Expiration Date: 7/19/2019
Credit Type: CMENumber of Credits: 0
Content Type: LectureProvider:
Biosimilars are very much alike but not identical to an FDA-approved reference biologic compound, with no meaningful differences in quality, safety, or efficacy. Used widely in Europe since 2006, the first biosimilar agent for use in the United States was approved in March 2015, and now several biosimilars are FDA-approved. As more biosimilars become available for use in the United States, all members of the multidisciplinary care team will require education on the appropriate incorporation of these agents into existing treatment paradigms. The faculty of this CME activity will provide an overview of biosimilars as well as a review of the latest safety and efficacy data regarding the use of biosimilars relevant to gastroenterology.